Search Result

Results for "

Aromatases Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (3) Apoptosis (5) Aryl Hydrocarbon Receptor (3) Autophagy (3) Bacterial (1) Biochemical Assay Reagents (1) Cytochrome P450 (55) Drug Intermediate (1) Drug Isomer (1) Drug Metabolite (3) EGFR (1) Endogenous Metabolite (1) ERK (2) Estrogen Receptor/ERR (7) Fungal (3) Isotope-Labeled Compounds (7) LDLR (1) MMP (2) Monoamine Oxidase (3) NF-κB (2) NO Synthase (1) p38 MAPK (2) PAI-1 (2) Parasite (3) Phosphodiesterase (PDE) (2) PPAR (2) Progesterone Receptor (3) PROTACs (1)
By Research Areas:	Cancer (42) Cardiovascular Disease (4) Endocrinology (25) Infection (4) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (3)

By Targets:

Androgen Receptor (3)

Apoptosis (5)

Aryl Hydrocarbon Receptor (3)

Autophagy (3)

Bacterial (1)

Biochemical Assay Reagents (1)

Cytochrome P450 (55)

Drug Intermediate (1)

Drug Isomer (1)

Drug Metabolite (3)

EGFR (1)

Endogenous Metabolite (1)

ERK (2)

Estrogen Receptor/ERR (7)

Fungal (3)

Isotope-Labeled Compounds (7)

LDLR (1)

MMP (2)

Monoamine Oxidase (3)

NF-κB (2)

NO Synthase (1)

p38 MAPK (2)

PAI-1 (2)

Parasite (3)

Phosphodiesterase (PDE) (2)

PPAR (2)

Progesterone Receptor (3)

PROTACs (1)

By Research Areas:

Cancer (42)

Cardiovascular Disease (4)

Endocrinology (25)

Infection (4)

Inflammation/Immunology (5)

Metabolic Disease (3)

Neurological Disease (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155493

CYP19A1/CYP11B2-IN-1	Cytochrome P450	Cancer
CYP19A1/CYP11B2-IN-1 (Compound X21) is a potent and selective *aromatase* and aldosterone synthase dual inhibitor with IC₅₀s of 2.3 nM and 29 nM for aromatase (CYP19A1) and aldosterone synthase (CYP11B2), respectively. CYP19A1/CYP11B2-IN-1 has excellent antiproliferative and pro-apoptotic activity against the cancer cell. CYP19A1/CYP11B2-IN-1 can be used for research of breast cancer .

HY-14274

Anastrozole 4 Publications Verification ZD1033	Cytochrome P450	Cancer
Anastrozole is a potent, highly selective *aromatase* inhibitor, which inhibits human placental aromatase with an IC₅₀ of 15 nM.

HY-148430

Aromatase-IN-2	Cytochrome P450	Cancer
Aromatase-IN-2 is a potent *aromatase* inhibitor with an IC₅₀ value of 1.5 µM .

HY-150775

*Nonsteroidal aromatase* inhibitor 1**	Cytochrome P450	Cancer
Nonsteroidal aromatase inhibitor 1 (Compound 13h) is a nonsteroidal *aromatase* (CYP19A1) inhibitor (IC₅₀=0.09 nM). Nonsteroidal aromatase inhibitor 1 has potential for breast cancer research . Nonsteroidal aromatase inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W739700

(R)-(+)-Aminoglutethimide L-Tartrate d-Aminoglutethimide L-Tartrate	Cytochrome P450	Inflammation/Immunology
(R)-(+)-Aminoglutethimide (L-Tartrate) is an inhibitor of *aromatase. (R)-(+)-Aminoglutethimide inhibits* androstenedione with a K_i value of 0.3 μM .

HY-162105

Aromatase-IN-3	Cytochrome P450	Endocrinology Cancer
Aromatase-IN-3 (compound 7d) is an *aromatase* inhibitor with an IC₅₀ of 54 nM. Through suppressing the conversion of androstenedione to oestrogen caused by aromatase, Aromatase-IN-3 exerts an appreciable tumor growth inhibitory activities against breast cancer cell lines, suggesting its usage for ER+ cancer research .

HY-113986B

(S)-Dexfadrostat (S)-Fadrozole; (S)-CGS 16949A free base; (S)-FAD286	Cytochrome P450	Inflammation/Immunology Endocrinology Cancer
(S)-Dexfadrostat ((S)-Fadrozole) is an aromatase inhibitor with an IC₅₀ of 4.6 nM in human placental microsomes in vitro. (S)-Dexfadrostat can be used in the study of estrogen-dependent breast cancer, gynecomastia, and systemic lupus erythematosus .

HY-144824

Monoamine oxidase/Aromatase-IN-1	Cytochrome P450 Monoamine Oxidase	Neurological Disease Cancer
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent monoamine oxidase (MAO) and *aromatase* dual inhibitor with IC₅₀s of 39 nM and 31 nM for MAO-B and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer .

HY-170508

Aromatase-IN-4	Cytochrome P450	Endocrinology
Aromatase-IN-4 (Compound 6a) is an aromatase (Aromatase) inhibitor. Aromatase-IN-4 exhibits anticancer activity, with GI₅₀ values of 2.95 μM, 3.35 μM, 2.27 μM, 8.46 nM, and 1.56 μM against the MDAMB-231, MCF-7, A-549, NCI-H23, and A-498 cell lines, respectively . Aromatase-IN-4 effectively blocks aromatase-dependent estrogen production .

HY-14274R

Anastrozole (Standard) ZD1033 (Standard)	Cytochrome P450	Cancer
Anastrozole (Standard) is the analytical standard of Anastrozole. This product is intended for research and analytical applications. Anastrozole is a potent, highly selective *aromatase* inhibitor, which inhibits human placental aromatase with an IC₅₀ of 15 nM.

HY-14274S

Anastrozole-d12 ZD1033-d₁₂	Isotope-Labeled Compounds Cytochrome P450	Cancer
Anastrozole-d₁₂ is the deuterium labeled Anastrozole. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM[1][2].

HY-U00176

Org30958	Cytochrome P450	Metabolic Disease
Org30958 is a potent *aromatase* inhibitor in vivo.

HY-B0237

Aminoglutethimide DL-Aminoglutethimide	Cytochrome P450	Endocrinology
Aminoglutethimide is an aromatase inhibitor with IC50 of 10 μM.

HY-N5012

Eurycomanone Pasakbumin A	Phosphodiesterase (PDE)	Endocrinology
Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.

HY-137931

Testololactone	Cytochrome P450	Cancer
Testololactone is an *aromatase* inhibitor. Testololactone can be used for research of breast carcinoma .

HY-14247

Fadrozole hydrochloride 2 Publications Verification CGS 16949A; (Rac)-FAD286 hydrochloride	Cytochrome P450	Endocrinology Cancer
Fadrozole hydrochloride (CGS 16949A) is a potent, selective and nonsteroidal inhibitor of *aromatase* with an IC₅₀ of 6.4 nM.

HY-13632

Exemestane 4 Publications Verification FCE 24304; EXE	Cytochrome P450	Endocrinology Cancer
Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal *aromatase* inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .

HY-14247A

Fadrozole 2 Publications Verification CGS 16949A free base; (Rac)-FAD286	Cytochrome P450	Cancer
Fadrozole (CGS 16949A free base) is a potent, selective and nonsteroidal inhibitor of *aromatase* with an IC₅₀ of 6.4 nM.

HY-W392925

(R)-(+)-Aminoglutethimide d-Aminoglutethimide	Cytochrome P450	Cancer
(R)-(+)-Aminoglutethimide is a potent and orally active *aromatase* inhibitor. (R)-(+)-Aminoglutethimide has the potential for the research of breast cancer .

HY-13632S

Exemestane-d2 FCE 24304-d₂; EXE-d₂	Isotope-Labeled Compounds Cytochrome P450	Endocrinology Cancer
Exemestane-d₂ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632S2

Exemestane-d3 FCE 24304-d₃; EXE-d₃	Isotope-Labeled Compounds Cytochrome P450	Endocrinology Cancer
Exemestane-d₃ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632S1

Exemestane-13C3	Isotope-Labeled Compounds Cytochrome P450	Endocrinology Cancer
Exemestane- ¹³C₃ is the ¹³C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632R

Exemestane (Standard) 4 Publications Verification FCE 24304(Standard); EXE (Standard)	Cytochrome P450	Endocrinology Cancer
Exemestane (Standard) is the analytical standard of Exemestane. This product is intended for research and analytical applications. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal *aromatase* inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .

HY-146688

SYN20028567	Cytochrome P450	Cancer
SYN20028567 is an aromatase (CYP19) inhibitor with an IC₅₀ of 9.4 nM. SYN20028567 can be used for breast cancer research .

HY-105375

FR 901537	Cytochrome P450	Cancer
FR 901537 is a potent and competitive *aromatase* inhibitor. FR 901537, a novel naphthol derivative, has the potential for breast cancer research .

HY-105184

YM511	Cytochrome P450	Endocrinology
YM511 is a highly specific non-steroidal *aromatase* inhibitor. YM511 inhibits aromatase activities in microsomes from rat ovary and human placenta competitively (IC50s of 0.4 and 0.12 nM, respectively). YM511 slightly inhibits production of other steroid hormones. YM511 has the potential for suppressing estrogen-dependent action research without affecting serum levels of other steroid hormones .

HY-159741

Minamestane FCE 24928	Cytochrome P450	Cancer
Minamestane (FCE 24928) is a selective and competitive *aromatase* inhibitor with an IC₅₀ value of 45.7 nM. Minamestane is promising for research of postmenopausal breast cancer .

HY-Z4488

5-Dibromomethyl anastrozole	Drug Intermediate	Cancer
5-Dibromomethyl anastrozole is a synthetic intermediate in the synthesis of the aromatase/CYP19A1 inhibitor Anastrozole (HY-14274).

HY-N5012R

Eurycomanone (Standard)	Phosphodiesterase (PDE)	Endocrinology
Eurycomanone (Standard) is the analytical standard of Eurycomanone. This product is intended for research and analytical applications. Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.

HY-123247

LY113174	Cytochrome P450	Endocrinology
LY113174 is an orally active *aromatase* inhibitor (IC₅₀ = 24 nM). LY113174 blocks testosterone induced increase in uterine weight in rat, and inhibits ovarian estrogen biosynthesis .

HY-13632S5

Exemestane-13C,d2 FCE 24304-¹³C,d₂; EXE-¹³C,d₂	Cytochrome P450 Isotope-Labeled Compounds	Endocrinology Cancer
Exemestane- ¹³C,d₂ is ¹³C and deuterated labeled Exemestane (HY-13632). Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal *aromatase* inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .

HY-105163

Finrozole MPV-2213ad	Cytochrome P450	Endocrinology
Finrozole (MPV-2213ad) is a nonsteroidal, orally active and competitive *aromatase* enzyme inhibitor. Finrozole can be used for urinary symptoms research .

HY-19599A

(Rac)-Vorozole (Rac)-R83842	Cytochrome P450 Drug Isomer	Others
(Rac)-Vorozole ((Rac)-R83842) is a racemate of Vorozole. Vorozole (HY-19599) is a potent and selective, orally active non-steroidal aromatase inhibitor .

HY-167737

(-)-Vorozole	Cytochrome P450	Cancer
(-)-Vorozole is an orally active non-steroidal aromatase inhibitor with potent and selective properties. (-)-Vorozole demonstrates antitumor activity in in vivo experiments. (-)-Vorozole is utilized in the study of breast cancer.

HY-18719B

Endoxifen hydrochloride 1 Publications Verification	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study .

HY-18719E

Endoxifen 1 Publications Verification	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study .

HY-19599

Vorozole (+)-Vorozole; R83842	Cytochrome P450	Cancer
Vorozole is a potent and selective, orally active non-steroidal *aromatase* inhibitor . Vorozole shows antitumor activity in vivo. Vorozole has the potential for the research of mammary cancer .

HY-14248

Letrozole Maximum Cited Publications 16 Publications Verification CGS 20267	Cytochrome P450 Autophagy	Cancer
Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of *aromatase, with an IC₅₀* of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer .

HY-125833

Alpha-Naphthoflavone 5+ Cited Publications	Cytochrome P450 Aryl Hydrocarbon Receptor Apoptosis	Cancer
Alpha-Naphthoflavone is an orally active flavonoid that is a potent, competitive inhibitor of aromatase< b>aromatase. < b > IC < sub > 50 < / sub > < / b > and < b > K < sub > I < / sub > < / b > value were 0.5 and 0.2 microns. Alpha-Naphthoflavone can inhibit cell proliferation and induce apoptosis .

HY-W087008

7-Hydroxyflavanone	Cytochrome P450	Endocrinology Cancer
7-Hydroxyflavanone is a potent inhibitor of *aromatase* (CYP19) activity with the IC₅₀ of 65 μM. 7-Hydroxyflavanone exerts various biological effects, including anticarcinogenic, antioxidant and (anti-)estrogenic effects, and modula

HY-113986

Dexfadrostat (R)-Fadrozole; (R)-CGS 16949A free base; FAD286	Cytochrome P450	Cardiovascular Disease
Dexfadrostat ((R)-Fadrozole) is a potent nonsteroidal inhibitor . Dexfadrostat also inhibits human placental aromatase (pIC₅₀ = 6.17) and aldosterone biosynthesis. Dexfadrostat reverses cardiac fibrosis in spontaneously hypertensive heart failure rats. .

HY-N3246

Morachalcone A	NO Synthase	Inflammation/Immunology
Morachalcone A is a naturally-occurring aromatase inhibitor (IC₅₀=4.6 mM). Morachalcone A is also a plants metabolite with potential anti-inflammatory and anticancer activity. Morachalcone A inhibits Lipopolysaccharide (HY-D1056)-induced nitric oxide production .

HY-18719ES

Endoxifen-d5	Cytochrome P450 Estrogen Receptor/ERR Drug Metabolite Parasite	Cancer
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

HY-N7128

Flavanone	Cytochrome P450 ERK p38 MAPK NF-κB MMP PAI-1	Cancer
Flavanone is a naturally occurring flavone. Flavanone has inhibitory activity for human estrogen synthetase (aromatase). Flavanone is the inhibitor for ERK/p38/NF-κB signaling pathway. Flavanone exhibits oral activity and antitumor efficacy .

HY-113062

20α-Dihydroprogesterone 20-OH-P	Endogenous Metabolite Cytochrome P450	Endocrinology Cancer
20α-Dihydroprogesterone is the metabolite of Progesterone (HY-N0437). 20α-Dihydroprogesterone inhibits cell proliferation and migration in breast tissue. 20α-Dihydroprogesterone inhibits *aromatase* in cell MCF-7aro with IC₅₀ about 5 μM .

HY-14247B

Fadrozole hydrochloride hemihydrate CGS 16949A hemihydrate; (Rac)-FAD286 hydrochloride hemihydrate	Cytochrome P450	Endocrinology Cancer
Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidal *aromatase* inhibitor, with an IC₅₀ of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, with IC₅₀ values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease and cancer .

HY-14248R

Letrozole (Standard)	Cytochrome P450 Autophagy	Cancer
Letrozole (Standard) is the analytical standard of Letrozole. This product is intended for research and analytical applications. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer .

HY-136063

Mefentrifluconazole	Fungal Cytochrome P450	Infection
Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum antifungal agent. Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (K_d= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC₅₀=0.92 μM) .

HY-118178

LY43578	Cytochrome P450 Monoamine Oxidase	Cardiovascular Disease
LY43578 is an orally active *aromatase* inhibitor. LY43578 inhibits P-450-dependent p-nitroanisole O-demethylation and ethylmorphine N-demethylation in hepatic microsomes isolated from rat, with the IC₅₀ of 0.3 and 5 μΜ, respectively. LY43578 can be used for neurological disorder study .

HY-118407

LY56110	Cytochrome P450 Monoamine Oxidase	Neurological Disease
LY56110 is an orally active *aromatase* inhibitor. LY56110 inhibits P-450-dependent p-nitroanisole O-demethylation and ethylmorphine N-demethylation in hepatic microsomes isolated from rat, with the IC₅₀ of 2.5 and 11 μΜ, respectively. LY56110 can be used for neurological disorder study .

Cat. No.	Product Name	Type

HY-W699238

S-(-)-Aminoglutethimide D-tartrate

Cell Assay Reagents

S-(-)-Aminoglutethimide D-tartrate is an aromatase inhibitor with activity that blocks adrenal steroidogenesis. S-(-)-Aminoglutethimide D-tartrate can be used to inhibit steroid-related diseases. S-(-)-Aminoglutethimide D-tartrate is often used clinically to control certain types of cancer. S-(-)-Aminoglutethimide D-tartrate effectively reduces testosterone and estrogen levels through an enzyme inhibition mechanism.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N5012

Eurycomanone Pasakbumin A	Structural Classification other families Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Disease Research Fields Endocrinology	Phosphodiesterase (PDE)
Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.

HY-14248

Letrozole Maximum Cited Publications 16 Publications Verification CGS 20267	Alkaloids Classification of Application Fields Other Alkaloids Source classification Plants Compositae Disease Research Fields Tephrosia purpurea (L.) Pers. Cancer	Cytochrome P450 Autophagy
Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of *aromatase, with an IC₅₀* of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer .

HY-125833

Alpha-Naphthoflavone 5+ Cited Publications	Flavonoids Flavones Source classification Indigofera heterantha Wall. ex Brand. Plants Compositae Disease Research Fields Cancer	Cytochrome P450 Aryl Hydrocarbon Receptor Apoptosis
Alpha-Naphthoflavone is an orally active flavonoid that is a potent, competitive inhibitor of aromatase< b>aromatase. < b > IC < sub > 50 < / sub > < / b > and < b > K < sub > I < / sub > < / b > value were 0.5 and 0.2 microns. Alpha-Naphthoflavone can inhibit cell proliferation and induce apoptosis .

HY-W087008

7-Hydroxyflavanone	Dalbergia cochinchinensis Monophenols Source classification Papilionaceae Phenols Plants Disease Research Fields Endocrinology Cancer	Cytochrome P450
7-Hydroxyflavanone is a potent inhibitor of *aromatase* (CYP19) activity with the IC₅₀ of 65 μM. 7-Hydroxyflavanone exerts various biological effects, including anticarcinogenic, antioxidant and (anti-)estrogenic effects, and modula

HY-N7128

Flavanone	Structural Classification Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Sophora flavescens Aiton Plants Disease Research Fields Cancer	Cytochrome P450 ERK p38 MAPK NF-κB MMP PAI-1
Flavanone is a naturally occurring flavone. Flavanone has inhibitory activity for human estrogen synthetase (aromatase). Flavanone is the inhibitor for ERK/p38/NF-κB signaling pathway. Flavanone exhibits oral activity and antitumor efficacy .

HY-113062

20α-Dihydroprogesterone 20-OH-P	Structural Classification Animals Source classification Steroids	Endogenous Metabolite Cytochrome P450
20α-Dihydroprogesterone is the metabolite of Progesterone (HY-N0437). 20α-Dihydroprogesterone inhibits cell proliferation and migration in breast tissue. 20α-Dihydroprogesterone inhibits *aromatase* in cell MCF-7aro with IC₅₀ about 5 μM .

HY-105375

FR 901537	Structural Classification Monophenols Microorganisms Source classification Phenols	Cytochrome P450
FR 901537 is a potent and competitive *aromatase* inhibitor. FR 901537, a novel naphthol derivative, has the potential for breast cancer research .

HY-N5012R

Eurycomanone (Standard)	Structural Classification other families Terpenoids Source classification Diterpenoids Plants	Phosphodiesterase (PDE)
Eurycomanone (Standard) is the analytical standard of Eurycomanone. This product is intended for research and analytical applications. Eurycomanone could increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis.

HY-N3246

Morachalcone A	Structural Classification Source classification Phenols Polyphenols Plants Moraceae Morus alba Linn.	NO Synthase
Morachalcone A is a naturally-occurring aromatase inhibitor (IC₅₀=4.6 mM). Morachalcone A is also a plants metabolite with potential anti-inflammatory and anticancer activity. Morachalcone A inhibits Lipopolysaccharide (HY-D1056)-induced nitric oxide production .

HY-14248R

Letrozole (Standard)	Alkaloids Other Alkaloids Source classification Plants Compositae Tephrosia purpurea (L.) Pers.	Cytochrome P450 Autophagy
Letrozole (Standard) is the analytical standard of Letrozole. This product is intended for research and analytical applications. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer .

HY-N7128R

Flavanone (Standard)	Structural Classification Flavonoids Leguminosae Flavonones Source classification Sophora flavescens Aiton Plants	Cytochrome P450 ERK p38 MAPK NF-κB MMP PAI-1
Flavanone (Standard) is the analytical standard of Flavanone. This product is intended for research and analytical applications. Flavanone is a naturally occurring flavone. Flavanone has inhibitory activity for human estrogen synthetase (aromatase). lavanone is the inhibitor for ERK/p38/NF-κB signaling pathway. Flavanone exhibits oral activity and antitumor efficacy .

HY-N0292

Oleuropein 2 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Anti-aging Source classification Plants Burseraceae Iridoids Canarium album (Lour.) Rauesch. Terpenoids Phenols Polyphenols Inflammation/Immunology Disease Research Fields Cancer	Cytochrome P450 PPAR Apoptosis
Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits *aromatase* .

HY-N0292R

Oleuropein (Standard)	Structural Classification Iridoids Canarium album (Lour.) Rauesch. Terpenoids Source classification Phenols Polyphenols Plants Burseraceae	Cytochrome P450 PPAR Apoptosis
Oleuropein (Standard) is the analytical standard of Oleuropein. This product is intended for research and analytical applications. Oleuropein, found in olive leaves and oil, exerts antioxidant, anti-inflammatory and anti-atherogenic effects through direct inhibition of PPARγ transcriptional activity . Oleuropein induces apoptosis in breast cancer cells via the p53-dependent pathway and through the regulation of Bax and Bcl2 genes. Oleuropein also inhibits aromatase .

HY-N1993

5-Methyl-7-methoxyisoflavone 1 Publications Verification	Structural Classification Flavonoids other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields Isoflavones	Cytochrome P450
5-Methyl-7-methoxyisoflavone is an orally active anti-oxidant with remyelinating activity. 5-Methyl-7-methoxyisoflavone inhibits the enzyme *aromatase, interfering with the normal metabolic pathways of testosterone. 5-Methyl-7-methoxyisoflavone is a non-steroidal anabolic isoflavone, used as a anabolic agent*. 5-Methyl-7-methoxyisoflavone shows better potency increasing muscle mass and endurance than Ipriflavone (HY-N0094). 5-Methyl-7-methoxyisoflavone can be used for fat loss besides the maintenance of low cholesterol level and strengthen bones .

Cat. No.	Product Name	Chemical Structure

HY-14248S

Letrozole-d4
Letrozole-d₄ (CGS 20267-d4) is the deuterium labeled Letrozole. Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer[1][2][3].

HY-14274S

Anastrozole-d12
Anastrozole-d₁₂ is the deuterium labeled Anastrozole. Anastrozole is a potent, highly selective aromatase inhibitor, which inhibits human placental aromatase with an IC50 of 15 nM[1][2].

HY-13632S

Exemestane-d2
Exemestane-d₂ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632S2

Exemestane-d3
Exemestane-d₃ is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632S1

Exemestane-13C3
Exemestane- ¹³C₃ is the ¹³C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

HY-13632S5

Exemestane-13C,d2
Exemestane- ¹³C,d₂ is ¹³C and deuterated labeled Exemestane (HY-13632). Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal *aromatase* inhibitor with IC₅₀s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .

HY-18719ES

Endoxifen-d5
Endoxifen-d₅ is the deuterium labeled Endoxifen. Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study[1][2].

HY-B0084S4

Dienogest-13C,15N,d4

Dienogest-13C,15N,d4 (STS 557-13C,15N,d4) is the ¹³C, ¹⁵N and deuterium labeled isotope of Dienogest (HY-B0084). Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE₂ synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks